Dexcom EVP has shares withheld for RSU taxes

Dexcom EVP Jon Coleman had shares withheld to cover taxes on stock awards.

Rhea-AI Filing Summary

Dexcom EVP Jon Coleman had shares withheld to cover taxes on stock awards. On this Form 4, 7,362 shares of Dexcom common stock were surrendered at $71.90 per share to satisfy tax withholding obligations from the net settlement of restricted stock units, and this is explicitly stated not to be a sale.

After this tax withholding, Coleman directly holds 105,273 shares of Dexcom, including 95,450 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029 and May 22, 2029. This filing reflects routine compensation-related tax treatment rather than an open‑market trade.

Insider Trade Summary

Exercise Price or Tax Liability: 7,362 shares

Exercise Price or Tax Liability 1 txn

Insider Coleman Jon

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	7,362	$71.90	$529K

Holdings After Transaction: Common Stock — 105,273 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
2. F2. Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

Key Figures

Tax-withheld shares: 7,362 shares Withholding reference price: $71.90 per share Shares held after transaction: 105,273 shares +3 more

6 metrics

Tax-withheld shares 7,362 shares Shares withheld to cover tax obligations on RSU net settlement

Withholding reference price $71.90 per share Value used for the 7,362 tax-withheld shares

Shares held after transaction 105,273 shares Direct Dexcom common stock holdings following the tax withholding

Unvested RSUs total 95,450 units Restricted stock units unvested as part of Coleman's holdings

RSUs granted March 8, 2026 43,897 units Unvested RSUs vesting through March 8, 2029

RSUs granted May 22, 2025 51,553 units Unvested RSUs vesting through May 22, 2029

Key Terms

restricted stock units, net settlement, tax withholding, unvested restricted stock units

4 terms

restricted stock units financial

"in connection with the net settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"in connection with the net settlement of restricted stock units"

tax withholding financial

"required to be withheld by the Issuer to cover tax withholding and remittance obligations"

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

unvested restricted stock units financial

"Included in this number are 95,450 unvested restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) report for Jon Coleman?

Dexcom reported that EVP and Chief Commercial Officer Jon Coleman had 7,362 shares withheld to cover tax obligations on restricted stock units. This was an automatic tax-withholding disposition, not an open-market sale of Dexcom shares.

Did Dexcom EVP Jon Coleman sell shares in this Form 4 filing?

No, Jon Coleman did not sell shares in the market. The 7,362 shares shown were withheld by Dexcom to satisfy tax withholding and remittance obligations on vested restricted stock units, as clearly described in the filing footnotes.

How many Dexcom (DXCM) shares does Jon Coleman hold after this transaction?

After the tax-withholding transaction, Jon Coleman directly holds 105,273 Dexcom common shares. This figure includes a substantial portion represented by unvested restricted stock units that will vest over several future dates through 2029.

What restricted stock units does Dexcom EVP Jon Coleman have outstanding?

Coleman has 95,450 unvested restricted stock units outstanding. Of these, 43,897 were granted on March 8, 2026 and will vest through March 8, 2029, and 51,553 were granted on May 22, 2025 and will vest through May 22, 2029.

How should investors interpret the Form 4 tax-withholding for Dexcom (DXCM)?

The reported transaction reflects routine tax withholding tied to equity compensation, not a discretionary sale. Such Form 4 entries typically indicate administrative handling of taxes on vested restricted stock units rather than a change in the insider’s investment stance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Jon

(Last) (First) (Middle)

6430 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		F		7,362(1)	D	$71.9	105,273(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

2. Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Jon Coleman	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)